Acción Exact Sciences (EXAS)
Empresa del sector salud. Aquí tienes el precio, un resumen del negocio y lo que conviene saber sobre Exact Sciences en septiembre 2026.
Exact Sciences Corporation (EXAS) develops and commercialises non‑invasive cancer screening tests, best known for Cologuard, a stool‑based colorectal cancer screening product. Investors should know the company’s growth depends on test adoption, reimbursement from insurers and its ability to expand into other cancer diagnostics through product launches and acquisitions. Revenue has historically been driven by screening volumes, pricing and payer coverage; margins can improve as fixed costs scale but may be pressured by marketing and R&D investment. Key risks include regulatory and reimbursement uncertainty, competition from lab and diagnostic rivals, and execution challenges in commercial expansion and new test development. The stock can be volatile and is sensitive to changes in clinical data, guideline updates and policy decisions. With a market cap near $12bn, Exact Sciences may appeal to investors seeking exposure to diagnostic innovation, but it is not suitable for everyone — consider your risk tolerance and time horizon and seek independent advice before investing.
Pronóstico de la acción Exact Sciences (EXAS)
Precio objetivo de consenso de los analistas a 12 meses
$100.47
- Precio objetivo
- $100.47
Rango de 52 semanas
Los objetivos de los analistas son opiniones, no garantías. Capital en riesgo. Datos al 25 may 2026.
Fuente: el sentimiento de los analistas es proporcionado por Refinitiv Ltd, líder mundial en datos de mercados financieros con más de 40.000 clientes empresariales. Refinitiv Ltd es un tercero independiente de Nemo. Esto no es asesoramiento.
Rendimiento del crecimiento a seis meses
Resumen del rendimiento de la acción
Calificación de los analistas
Analysts suggest holding Exact Sciences stock with a target price of $100.47, indicating limited growth.
Salud financiera
Exact Sciences is performing well with strong revenue and profitability, indicating healthy business operations.
Ve más acciones descargando la app GRATIS
Solo toma 60 segundos.
Por qué querrás seguir esta acción
Screening growth potential
Colorectal screening adoption and expanded guidelines could drive volume, though uptake depends on reimbursement and patient behaviour, so outcomes can vary.
Expanding global reach
International roll‑out and partnerships may open new markets, but regulatory hurdles and local payer systems can slow progress and add uncertainty.
Pipeline and innovation
R&D and acquisitions aim to broaden cancer detection offerings; promising data can boost prospects, while negative results or delays present downside risk.
¿Por qué invertir con Nemo?
Cero comisiones
Opera acciones, ETF y más sin comisiones. Conserva una mayor parte de tus ganancias.
Confiable y regulado
Parte del grupo Exinity desde 2015, con más de un millón de clientes en todo el mundo.
